TriangleNCT03239145 · OUTCOME
Number of Participants Experienced Dose Limit Toxicities (DLT)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- 3 weeks
What was measured
A standard 3+3 dose-escalation design was used during dose escalation period. DLT was defined in protocol section 5.5.
Analysis population: DLTs will be monitored and collected for treated participants that enrolled during the dose escalation period.
Groups in this outcome
[Dose Escalation Dose Level I] Pembrolizumab + Trebananib
Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 15 mg/kg weekly. Pembrolizumab: Pembrolizumab is designed to augment the natural ability of the immune system to recognize and target cancer cells Trebananib: AMG386 is a drug that may kill tumor cells and blocks blood vessels that supply the tumor with nutrients and oxygen
[Dose Escalation Dose Level II] Pembrolizumab + Trebananib
Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 30 mg/kg weekly. Pembrolizumab: Pembrolizumab is designed to augment the natural ability of the immune system to recognize and target cancer cells Trebananib: AMG386 is a drug that may kill tumor cells and blocks blood vessels that supply the tumor with nutrients and oxygen
| Group | Source count |
|---|---|
| [Dose Escalation Dose Level I] Pembrolizumab + Trebananib | 3 |
| [Dose Escalation Dose Level II] Pembrolizumab + Trebananib | 3 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| [Dose Escalation Dose Level I] Pembrolizumab + Trebananib | 0 | Not reported | Not reported | Not reported | Not reported |
| [Dose Escalation Dose Level II] Pembrolizumab + Trebananib | 0 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- denoms
- counts
- group Id
- OG000
- value
- 3
- group Id
- OG001
- value
- 3
- units
- Participants
- description
- A standard 3+3 dose-escalation design was used during dose escalation period. DLT was defined in protocol section 5.5.
- groups
- description
- Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 15 mg/kg weekly. Pembrolizumab: Pembrolizumab is designed to augment the natural ability of the immune system to recognize and target cancer cells Trebananib: AMG386 is a drug that may kill tumor cells and blocks blood vessels that supply the tumor with nutrients and oxygen
- id
- OG000
- title
- [Dose Escalation Dose Level I] Pembrolizumab + Trebananib
- description
- Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 30 mg/kg weekly. Pembrolizumab: Pembrolizumab is designed to augment the natural ability of the immune system to recognize and target cancer cells Trebananib: AMG386 is a drug that may kill tumor cells and blocks blood vessels that supply the tumor with nutrients and oxygen
- id
- OG001
- title
- [Dose Escalation Dose Level II] Pembrolizumab + Trebananib
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- DLTs will be monitored and collected for treated participants that enrolled during the dose escalation period.
- reporting Status
- POSTED
- time Frame
- 3 weeks
- title
- Number of Participants Experienced Dose Limit Toxicities (DLT)
- type
- PRIMARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice